Immunosuppressive and immunomodulatory therapies in Sjögren’s disease: current landscape and future perspectives
Expert Opinion on Pharmacotherapy, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/14656566.2026.2734124
- Dergi Adı: Expert Opinion on Pharmacotherapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Anahtar Kelimeler: abatacept, belimumab, csDMARD, dazodalibep, ianalumab, iscalimab, rituximab, Sjögren’s disease
- Akdeniz Üniversitesi Adresli: Evet
Özet
Introduction: Sjögren’s disease (SjD) is a systemic autoimmune disorder primarily affecting exocrine glands alongside heterogeneous organ involvement. Historically managed through symptomatic relief and conventional disease-modifying therapies, recent immunological advances have steadily expanded our understanding of its pathogenesis and therapeutic approaches. Areas covered: A systematic literature review regarding therapeutic agents for SjD treatment was conducted across the PubMed, Web of Science, Embase, and Cochrane Library databases. Expert opinion: Over the past two decades, significant advancements in immunology have profoundly deepened our understanding of SjD pathogenesis. This pathophysiological insight is facilitating a paradigm shift from conventional symptomatic relief toward targeted, phenotype-driven biological interventions. The therapeutic pipeline investigating novel agents—including B-cell depletion therapies, BAFF/APRIL pathway inhibitors, T-cell/B-cell interaction modulators (e.g. CD40-CD40L, CTLA-4), type I interferon blockade, and JAK-STAT inhibitors—is expanding rapidly. CAR-T cell therapy application in refractory SjD patients currently represents an emerging, strictly experimental approach requiring rigorous evaluation of safety and long-term feasibility. Ultimately, identifying the most effective therapeutic agents will likely require discovering and implementing biomarkers tailored to specific biological endotypes.